N/A
N=19
Lens Fitting Evaluation of CooperVision MyDay™ Compared With 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1®
Myopia
Bottom Line
View on ClinicalTrials.gov: NCT02341859 ↗Enrolled (actual)
19
Serious AEs
0.0%
Results posted
May 2016
Primary outcome: Primary: Conjunctival Staining - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A — 0.42; 0.53; 0.68; 0.47 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- stenfilcon A (Device); delefilcon A (Device); narafilcon A (Device)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- CooperVision, Inc.
- Primary completion
- Jun 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Conjunctival Staining - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0.97; 0.79; 1.00; 1.29; 1.11; 0.47 | — |
| PRIMARY Conjunctival Staining - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0.97; 0.79; 1.00; 1.29; 1.11; 0.47 | — |
| PRIMARY Conjunctival Indentation - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0.05; 0.16; 0.26; 0.08; 0.18; 0.05 | — |
| PRIMARY Conjunctival Indentation - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0.05; 0.16; 0.26; 0.08; 0.18; 0.05 | — |
| PRIMARY Limbal Redness - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
1.08; 1.03; 1.05; 1.34; 1.00; 1.03 | — |
| PRIMARY Limbal Redness - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
1.08; 1.03; 1.05; 1.34; 1.00; 1.03 | — |
| PRIMARY Corneal Staining Type - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0.00; 0.08; 0.00; 0.03; 0.05; 0.08 | — |
| PRIMARY Corneal Staining Type - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0.00; 0.08; 0.00; 0.03; 0.05; 0.08 | — |
| PRIMARY Corneal Staining Extent - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0.00; 0.03; 0.00; 0.05; 0.11; 0.03 | — |
| PRIMARY Corneal Staining Extent - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0.00; 0.03; 0.00; 0.05; 0.11; 0.03 | — |
| PRIMARY Corneal Staining Depth - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0.00; 0.05; 0.00; 0.05; 0.05; 0.05 | — |
| PRIMARY Corneal Staining Depth - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0.00; 0.05; 0.00; 0.05; 0.05; 0.05 | — |
| PRIMARY Corneal Shape Change - Tangential Radius - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
-0.007; -0.004; 0.009; 0.017 | — |
| PRIMARY Corneal Shape Change - Wavefront Error - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0.004; -0.006; -0.006; 0.004 | — |
| PRIMARY Lens Fit - Corneal Coverage - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
19; 19; 19; 18; 0; 0 | — |
| PRIMARY Lens Fit - Corneal Coverage - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
19; 19; 19; 18; 0; 0 | — |
| PRIMARY Lens Fit - Horizontal Centration - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0; 0; 0; 2; 2; 1 | — |
| PRIMARY Lens Fit - Horizontal Centration - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0; 0; 0; 2; 2; 1 | — |
| PRIMARY Lens Fit - Vertical Centration - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Lens Fit - Vertical Centration - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Lens Fit - Post-blink Movement - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Lens Fit - Post-blink Movement - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Lens Fit - Tightness on up Gaze Blink Lag - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
16; 17; 17; 13; 3; 2 | — |
| PRIMARY Lens Fit - Tightness on up Gaze Blink Lag - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
16; 17; 17; 13; 3; 2 | — |
| PRIMARY Lens Fit Overall - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
18; 18; 19; 13; 1; 1 | — |
| PRIMARY Lens Fit Overall - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
18; 18; 19; 13; 1; 1 | — |
| SECONDARY Pain and Foreign Body Sensation (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
15; 15; 13; 11; 2; 3 | — |
| SECONDARY Pain and Foreign Body Sensation (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
15; 15; 13; 11; 2; 3 | — |
| SECONDARY Itching Sensation on Insertion (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
15; 17; 18; 16; 4; 2 | — |
| SECONDARY Itching Sensation on Removal (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
15; 16; 15; 14; 4; 3 | — |
| SECONDARY Red Eye (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
19; 19; 17; 16; 0; 0 | — |
| SECONDARY Dryness (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
91.3; 92.5; 93.0; 90.2; 87.8; 87.2 | — |
| SECONDARY Comfort (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
90.0; 92.7; 84.3; 84.6; 90.0; 88.4 | — |
| SECONDARY Handling (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
95.8; 93.0; 90.9; 91.3; 81.6; 86.4 | — |
| SECONDARY Vision (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
90.0; 94.1; 86.5; 90.6; 93.5; 96.8 | — |
| SECONDARY Overall Wearing Satisfaction (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
86.5; 88.6; 86.8; 83.4 | — |
| SECONDARY Lens Preferences (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A |
7; 11; 15; 4 | — |
Summary
Lens Fitting Evaluation of CooperVision MyDay™ Compared with 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1®
Eligibility Criteria
Inclusion Criteria
- Is between 18 and 40 years of age (inclusive)
- Has had a self-reported visual exam in the last two years
- Is an adapted soft spherical contact lens wearer
- Has a contact lens spherical prescription between -4.00 to - 6.00 and higher than -7.00D (Diopters) (inclusive)
- Has a BFS (Best Fit Sphere) that is higher than 8.2 measured and calculated by corneal topography
- Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye
- Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses
- Has clear corneas and no active ocular disease
- Has read, understood and signed the information consent letter
- Patient contact lens refraction should fit within the available parameters of the study lenses
- Is willing to comply with the wear schedule
- Is willing to comply with the visit schedule
Exclusion Criteria
- Is not a habitual wearer of soft spherical contact lenses
- Has a contact lens prescription outside the range of the available parameters of the study lenses
- Has a contact lens prescription outside the range of the inclusion power range
- Has a spectacle cylinder ≥1.00D of cylinder in either eye
- Has a history of not achieving comfortable contact lens wear (5 days per week; > 8 hours/day)
- Has contact lens best corrected distance vision worse than 20/25 (0.10 logMAR) in either eye
- Presence of clinically significant (grade > 2) anterior segment abnormalities
- Presence of ocular or systemic disease or need of medications which might interfere with contact lens wear
- Slit lamp findings that would contraindicate contact lens wear such as:
- Moderate to severe dry eye
- Pterygium, pinguecula, or corneal scars within the visual axis
- Neovascularization > 0.75 mm in from of the limbus
- Giant papillary conjunctivitis (GCP) worse than grade 1
- Anterior uveitis or iritis (past or present)
- Seborrheic eczema, Seborrheic conjunctivitis
- History of corneal ulcers or fungal infections
- Poor personal hygiene
- Has a known history of corneal hypoesthesia (reduced corneal sensitivity)
- Has aphakia, keratoconus or a highly irregular cornea
- Has Presbyopia or has dependence on spectacles for near work over the contact lenses
- Has undergone corneal refractive surgery
- Is participating in any other type of eye related clinical or research study
Data sourced from ClinicalTrials.gov (NCT02341859). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.